Evidence map›Paper›PMID 32289062›Full record

ArticleMaterials today. Communications2018

Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights.

Kumar Janakiraman, Venkateshwaran Krishnaswami, Vijaya Rajendran, Subramanian Natesan, Ruckmani Kandasamy

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kumar JanakiramanNational Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India.
Venkateshwaran KrishnaswamiNational Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India.
Vijaya RajendranNational Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India.
Subramanian NatesanNational Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India.
Ruckmani KandasamyNational Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India.
Anna University, Chennai · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is the most common complex multifactorial joint related autoimmune inflammatory disease with unknown etiology accomplished with increased cardiovascular risks. RA is characterized by the clinical findings of synovial inflammation, autoantibody production, and cartilage/bone destruction, cardiovascular, pulmonary and skeletal disorders. Pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and IL-10 were responsible for the induction of inflammation in RA patients. Drawbacks such as poor efficacy, higher doses, frequent administration, low responsiveness, and higher cost and serious side effects were associated with the conventional dosage forms for RA treatment. Nanomedicines were recently gaining more interest towards the treatment of RA, and researchers were also focusing towards the development of various anti-inflammatory drug loaded nanoformulations with an aid to both actively/passively targeting the inflamed site to afford an effective treatment regimen for RA. Alterations in the surface area and nanoscale size of the nanoformulations elicit beneficial physical and chemical properties for better pharmacological activities. These drug loaded nanoformulations may enhances the solubility of poorly water soluble drugs, improves the bioavailability, affords targetability and may improve the therapeutic activity. In this regimen, the present review focus towards the novel nanoparticulate formulations (nanoparticles, nanoemulsions, solid lipid nanoparticles, nanomicelles, and nanocapsules) utilized for the treatment of RA. The recent advancements such as siRNA, peptide and targeted based nanoparticulate systems for RA treatment were also discussed. Special emphasis was provided regarding the pathophysiology, prevalence and symptoms towards the development of RA.

Indexed as

ACF-SLN, aceclofenac loaded solid lipid nanoparticlesAIA, antigen-induced arthritisALP, alkaline phosphateALT, alanine aminotransferaseA-SLN, actarit loaded solid lipid nanoparticlesAST, aspartate aminotransferaseCEL-TS-LN, celecoxib loaded tristearin based lipidic nanoparticlesCFA, complete freund’s adjuvantCHNP, chitosan nanoparticleCLSM, confocal laser scanning microscopyCOX- 1, cyclooxygenase - 1COX- 2, cyclooxygenase - 2C-SLN, curcumin loaded solid lipid nanoparticlesDEX, dexamethasoneDEX-PMs, dexamethasone-loaded polymeric micellesDMARD, disease modifying antirheumatic drugsFA, folic acidFR-β, folate receptor-betaGC, glucocorticoidHA- AuNP/TCZ, hyaluronate gold nanoparticle/TocilizumabHEKcells, human embryonic kidney cellsHSA-NCs, human serum albumin nanocapsulesHUVEC, human umbilical vein cellsIg, immunoglobulinIL, interleukinInd-NCs, indomethacin-loaded nanocapsulesIND-NMs, indomethacin loaded polymeric micellesInflammationLDE, lipidic nanoemulsionLX-NMs, larnoxicam loaded nanomicellesmRNA, messenger RNAMTX-LCNCs, methotrexate-loaded lipidic core nanocapsulesNanoformulationNanoparticlesNSAIDs, non steroidal anti-inflammatory drugsPCL-PEG, poly (ethylene glycol)-block-poly (ε-caprolactone)PCL, polycaprolactonePir-SLN, piroxicam solid lipid nanoparticlesPSA-PCL-CyA-NMs, polysialic acid- polycaprolactone cyclosporine A nanomicellesPSA, polysialic acidP-SLN, piperine loaded solid lipid nanoparticleRA, rheumatoid arthritisRGD, arginine-glycine aspartic acidRheumatoid arthritisRNAi, RNA interferenceshRNA, short hairpin RNAsiRNA, small interfering RNASLN, solid lipid nanoparticlesTAC-HSA-NPs, tacrolimus human serum albumin nanoparticleTAC-LCNCs, tacrolimus loaded lipidic core nanocapsulesTNF-α, tumour necrosis factorVCAM-1, vascular cell adhesion molecule-1VEGF, vascular endothelial growth factorVIP, vasoactive intestinal peptide

Identifiers

PMID32289062
PMCPMC7104012
OpenAlexW2890717109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.